Compare · MGRX vs QIPT
MGRX vs QIPT
Side-by-side comparison of Mangoceuticals Inc. (MGRX) and Quipt Home Medical Corp. (QIPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGRX and QIPT operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- QIPT is the larger of the two at $166.8M, about 23.6x MGRX ($7.1M).
- QIPT has more recent analyst coverage (6 ratings vs 0 for MGRX).
- Company
- Mangoceuticals Inc.
- Quipt Home Medical Corp.
- Price
- -
- -
- Market cap
- $7.1M
- $166.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 6
Quipt Home Medical Corp.
Quipt Home Medical Corp. provides in-home monitoring equipment and disease management services includes end-to-end respiratory solutions for patients in the United States. It offers daily and ambulatory aides; power mobility equipment; BiPAP and CPAP machines, nebulizers, oxygen concentrators, and ventilators; oxygen therapy; sleep apnea and PAP treatment equipment; and home ventilator equipment, as well as rents respiratory equipment. The company also offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. was incorporated in 1993 and is headquartered in Wilder, Kentucky.
Latest MGRX
- SEC Form 10-K filed by Mangoceuticals Inc.
- SEC Form NT 10-K filed by Mangoceuticals Inc.
- SEC Form 4 filed by Cohen Jacob D.
- SEC Form 4 filed by Cohen Jacob D.
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
- Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest QIPT
- SEC Form 15-12G filed by Quipt Home Medical Corp.
- Amendment: SEC Form SCHEDULE 13D/A filed by Quipt Home Medical Corp.
- Director Wessel Brian Joseph returned $787,411 worth of shares to the company (215,729 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- Chief Accounting Officer Roehrig Thomas returned $631,450 worth of shares to the company (173,000 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- Chief Compliance Officer Miles Mark Alan returned $401,500 worth of shares to the company (110,000 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- Director Greenberg Mark Alan returned $1,589,418 worth of shares to the company (435,457 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- Exec. VP Operations Gamble Patrick Dennis returned $219,208 worth of shares to the company (60,057 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- President/CEO Crawford Gregory John returned $16,755,427 worth of shares to the company (4,590,528 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- Director Carter Kevin A. returned $734,234 worth of shares to the company (201,160 units at $3.65), closing all direct ownership in the company (SEC Form 4)
- Exec. VP Operations Bachelder David returned $80,869 worth of shares to the company (22,156 units at $3.65), closing all direct ownership in the company (SEC Form 4)